313 related articles for article (PubMed ID: 38542380)
21. Local estrogen axis in the human bone microenvironment regulates estrogen receptor-positive breast cancer cells.
Amanatullah DF; Tamaresis JS; Chu P; Bachmann MH; Hoang NM; Collyar D; Mayer AT; West RB; Maloney WJ; Contag CH; King BL
Breast Cancer Res; 2017 Nov; 19(1):121. PubMed ID: 29141657
[TBL] [Abstract][Full Text] [Related]
22. The curability of breast cancer and the treatment of advanced disease.
Guarneri V; Conte PF
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S149-61. PubMed ID: 15107948
[TBL] [Abstract][Full Text] [Related]
23. Profile and Outcome of Supraclavicular Metastases in Patients with Metastatic Breast Cancer: Discordance of Receptor Status Between Primary and Metastatic Site.
Thangarajah F; Vogel C; Pahmeyer C; Eichler C; Holtschmidt J; Ratiu D; Mallmann P; Malter W
Anticancer Res; 2018 Oct; 38(10):6023-6026. PubMed ID: 30275235
[TBL] [Abstract][Full Text] [Related]
24. Pathological Crosstalk between Metastatic Breast Cancer Cells and the Bone Microenvironment.
Zarrer J; Haider MT; Smit DJ; Taipaleenmäki H
Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32092997
[TBL] [Abstract][Full Text] [Related]
25. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome.
Lobbezoo DJ; van Kampen RJ; Voogd AC; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FP; van Riel JM; Peters NA; de Boer M; Borm GF; Tjan-Heijnen VC
Breast Cancer Res Treat; 2013 Oct; 141(3):507-14. PubMed ID: 24104881
[TBL] [Abstract][Full Text] [Related]
26. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Jiang Z; Li W; Hu X; Zhang Q; Sun T; Cui S; Wang S; Ouyang Q; Yin Y; Geng C; Tong Z; Cheng Y; Pan Y; Sun Y; Wang H; Ouyang T; Gu K; Feng J; Wang X; Wang S; Liu T; Gao J; Cristofanilli M; Ning Z; Lu X
Lancet Oncol; 2019 Jun; 20(6):806-815. PubMed ID: 31036468
[TBL] [Abstract][Full Text] [Related]
27. Single-Agent Oral Vinorelbine as First-Line Chemotherapy for Endocrine-Pretreated Breast Cancer With Bone Metastases and No Visceral Involvement: NORBREAST-228 Phase II Study.
Steger GG; Dominguez A; Dobrovolskaya N; Giotta F; Tubiana-Mathieu N; Pecherstorfer M; Ardizzoia A; Blasinska-Morawiec M; Espinosa E; Villanova G
Clin Breast Cancer; 2018 Feb; 18(1):e41-e47. PubMed ID: 28666812
[TBL] [Abstract][Full Text] [Related]
28. Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status.
Park YH; Lee S; Cho EY; Choi YL; Lee JE; Nam SJ; Yang JH; Ahn JS; Im YH
Cancer Chemother Pharmacol; 2010 Aug; 66(3):507-16. PubMed ID: 19956951
[TBL] [Abstract][Full Text] [Related]
29. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy.
Burstein HJ; Lieberman G; Slamon DJ; Winer EP; Klein P
Ann Oncol; 2005 Nov; 16(11):1772-7. PubMed ID: 16150805
[TBL] [Abstract][Full Text] [Related]
30. Treatment patterns and real world clinical outcomes in ER+/HER2- post-menopausal metastatic breast cancer patients in the United States.
Zanotti G; Hunger M; Perkins JJ; Horblyuk R; Martin M
BMC Cancer; 2017 Jun; 17(1):393. PubMed ID: 28578656
[TBL] [Abstract][Full Text] [Related]
31. Antrodia cinnamomea is a potentially effective complementary medicine for adjuvant therapy against breast cancer with bone metastasis: A case report.
Long H; Hu CT; Prijatelj V; Weng CF
Medicine (Baltimore); 2020 Jul; 99(27):e20808. PubMed ID: 32629666
[TBL] [Abstract][Full Text] [Related]
32. Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity.
Frassoldati A; Biganzoli L; Bordonaro R; Cinieri S; Conte P; Laurentis M; Mastro LD; Gori S; Lauria R; Marchetti P; Michelotti A; Montemurro F; Naso G; Pronzato P; Puglisi F; Tondini CA
Future Oncol; 2020 Feb; 16(5):129-145. PubMed ID: 31849236
[TBL] [Abstract][Full Text] [Related]
33. An update on the currently available and future chemotherapy for treating bone metastases in breast cancer patients.
Oruç Z; Kaplan MA; Arslan Ç
Expert Opin Pharmacother; 2018 Aug; 19(12):1305-1316. PubMed ID: 30129373
[TBL] [Abstract][Full Text] [Related]
34. Importance of confirming HER2 overexpression of recurrence lesion in breast cancer patients.
Nakamura R; Yamamoto N; Onai Y; Watanabe Y; Kawana H; Miyazaki M
Breast Cancer; 2013 Oct; 20(4):336-41. PubMed ID: 22367960
[TBL] [Abstract][Full Text] [Related]
35. Comparison of Predictive Immunohistochemical Marker Expression of Primary Breast Cancer and Paired Distant Metastasis using Surgical Material: A Practice-Based Study.
Kulka J; Székely B; Lukács LV; Kiss O; Tőkés AM; Vincze E; Turányi E; Fillinger J; Hanzély Z; Arató G; Szendrői M; Győrffy B; Szász AM
J Histochem Cytochem; 2016 Apr; 64(4):256-67. PubMed ID: 27029768
[TBL] [Abstract][Full Text] [Related]
36. Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis.
Haider MT; Holen I; Dear TN; Hunter K; Brown HK
Bone; 2014 Sep; 66(100):240-50. PubMed ID: 24971713
[TBL] [Abstract][Full Text] [Related]
37. Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Metastatic Breast Cancer in Young Women: Emerging Data in the Era of Molecularly Targeted Agents.
Shah AN; Metzger O; Bartlett CH; Liu Y; Huang X; Cristofanilli M
Oncologist; 2020 Jun; 25(6):e900-e908. PubMed ID: 32176406
[TBL] [Abstract][Full Text] [Related]
38. First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer.
Peron J; Tredan O; Ray-Coquard I; Bachelot T; Labidi Galy SI; Favier B; Treilleux I; Guastalla JP
Bull Cancer; 2012 Feb; 99(2):E18-25. PubMed ID: 22257781
[TBL] [Abstract][Full Text] [Related]
39. Metastasis prevention with bone-targeted agents: a complex interaction between the microenvironment and tumour biology.
Coleman R
J Bone Miner Metab; 2023 May; 41(3):290-300. PubMed ID: 37162605
[TBL] [Abstract][Full Text] [Related]
40. Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer.
Yardley DA; Kaufman PA; Brufsky A; Yood MU; Rugo H; Mayer M; Quah C; Yoo B; Tripathy D
Breast Cancer Res Treat; 2014 Jun; 145(3):725-34. PubMed ID: 24706168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
